Kovímba ya prostáti

Útá Wikipedia.
Kokɛndɛ na: bolúki, boluki

Kovímba ya prostáti, eyebani mpe bo carcinome ya prostáti, ezalí kopanzana ya  cancer nakati ya prostáti, oyo ezali glande nakati ya esika ya kobotisana na nzoto ya mobali.[1] Ba cancer mingi ya prostáti ekolaka malembe malembe; kasi, misusu ekolaka kamua noki.[2][3] Ba cellule ya cancer ekoki kopanzana kowuta na prostáti kino na biteni misusu ya nzoto, mingi mpeza na mikuwa mpe na ba vaisseaux ya lymphe.[4] Na ebandeli ekoki kolakisa bilembo te.[3] Na bileko misusu na sima, ekoki komema mpasi mpo na kosuba, makali nakati ya masuba, to mpasi na loketo, mokongo to ntango ya kosuba.[5] Bokono boye boyebani bo hypertrophie bénigne ya prostáti ekoki kolakisa bilembo ndenge moko na oyo. Bilembo misusu biye bimonana na sima bikoki kozala koyaka bolembu kolandana na motango moke ya ba globules rouges.[3]

Ba facteurs eye ekoki kobakisa risque ya kovímba ya prostáti ezalí: kimobange, lisitwale ya bokono soki esi ezwa moko nakati ya libota, mpe mokobo. Pene na 99% ya ba cas ekomelaka baye baza na mibu koleka 50. Kozala na ndeko ya pene mpeza ebakisaka risque mbala 2 kino 3. Na Etats Unis ezwaka mingi bayi Amerika bakitani ya Afrika koleka Mindele ya Amerika. Ba facteurs misusu ekoki kozala bilei oyo eza na ebele ya misunyi miye mibongolami na ba usine, misunyi ya motane, to biye bisalemaka kowuta na miliki to eza na ndunda moke.[2] Emonani ete bokono elandanaka mpe na gonorrhée , kasi ntina ya bolandani nayango naino emonani te.[6] Diagnostic ya kovímba ya prostáti esalemaka na nzela ya biopsie. Kozwa bilili na labo ekoki kosalema mpo na kososola soki cancer epanzani na biteni misusu ya nzoto.[5]

Depistage ya kovímba ya prostáti ezalaka na mingi ya maye malobamaka.[2][3] Examen ya antigène spécifique ya prostáti (ASP) ebakisaka makoki ya kokundola cancer kasi ekitisaka liwa te.[7] Task Force ya Services ya Prevention na Etats Unis esengaka ete pembeni ya depistage basala mpe examen ya ASP, mpo na risque ya kolekisa diagnostic mpe kolekisa nkisi mpo ete batu mingi oyo diagnostic ekolakisa ete bazali na cancer bakoki kokoba kozala asymptomatique. Task Force ya Prevention (USPSTF) esukisaki na koloba ete maye mazali ya litomba na bosali examen maleki te mpasi eye ekoki kozala.[8] Ntango ba inhibiteurs réductases-5α emonani neti ekitisaka risque ya kovímba ya moke esalaka eloko moto te mpo na risque ya kovímba ya monene nayango ezalaka recommandé te mpo na prevention.[2] Ba supplements na ba vitamines to ba minéraux emonani te ete esalaka eloko moko na risque.[2][9]

Ba cas mingi ekoki kolandelama malamu na surveillance active to kosinzila na bokebi. Traitement misusu ekoki kozala lipaso ya ndenge na ndenge, radiothérapie, hormonothérapie to chimiothérapie.[5] Ntango esalemi kaka nakati ya prostate ekoki kobikisama.[3] Epayi ya baye bokono epanzani tii na mikuwa, nkisi ya kosilisa mpasi (ba calmants), bisphosphonates na ba nkisi misusu eye esengeli ekoki kozala ya litomba. Ba resultats elandanaka na mibu ya mutu mpe mikakatano misusu ya nzoto na mpe lolenge ya cancer soki ezali ya yiki-yiki to ya kopanzana. Batu mingi oyo bazali na kovímba ya prostáti basukaka na liwa te kowuta na bokono oyo.[5] Taux ya survie ya mibu mitano na Etats Unis eza 99%.[10] Na mokili mobimba, bokono oyo eza ya mibale na lolenge ya cancer oyo ezwaka batu mingi mpe ntina ya mitano na liwa kowuta na cancer.[11] Na mobu ya 2012 ezwaki mibali 1.1 million mpe ememaki liwa ya batu 307,000.[11] Yango ezalaki cancer oyo ezwaki mingi nakati ya ba mboka 84,[2] kobimelaka mingi nakati ya ba pays développés. Taux nayango eza kokoba komata na ba pays en voie de développement.[12] Bokono oyo ekundolamaki mingi kati ya mibu ya 1980 na 1990 na bisika ebele kolandana ba examen mingi ya ASP.[2] Ba etudes ya mibali oyo bakufaki na ntina eye ezwami te na bokono emonaki kovímba ya prostáti na 30% kino 70% na baye baza na mibu koleka 60.[3]

References[kokoma | kobɔngisa mosólo]

  1. "Prostate Cancer". http://www.cancer.gov/cancertopics/types/prostate. Retrieved 12 October 2014. 
  2. 2,0, 2,1, 2,2, 2,3, 2,4, 2,5 et 2,6 (en) World Cancer Report 2014, World Health Organization,‎ 2014, Chapter 5.11 p. (ISBN 9283204298)
  3. 3,0, 3,1, 3,2, 3,3, 3,4 et 3,5 "Prostate Cancer Treatment (PDQ®)". 2014-04-11. http://www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional/page1/AllPages. Retrieved 1 July 2014. 
  4. (en) Raymond W. Ruddon, Cancer biology, Oxford, 4th,‎ 2007 (ISBN 9780195175431, lire en ligne), p. 223
  5. 5,0, 5,1, 5,2 et 5,3 "Prostate Cancer Treatment (PDQ®)". 2014-04-08. http://www.cancer.gov/cancertopics/pdq/treatment/prostate/Patient/page1/AllPages. Retrieved 1 July 2014. 
  6. Caini, Saverio; Gandini, Sara; Dudas, Maria; Bremer, Viviane; Severi, Ettore; Gherasim, Alin (2014). "Sexually transmitted infections and prostate cancer risk: A systematic review and meta-analysis". Cancer Epidemiology 38 (4): 329–338. doi:10.1016/j.canep.2014.06.002. PMID 24986642. 
  7. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P (2010). "Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials". BMJ 341: c4543. doi:10.1136/bmj.c4543. PMID 20843937. 
  8. "Talking With Your Patients About Screening for Prostate Cancer". http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatecancerscript.pdf. Retrieved 2012-07-02. 
  9. Stratton J, Godwin M (2011). "The effect of supplemental vitamins and minerals on the development of prostate cancer: A systematic review and meta-analysis". Family practice 28 (3): 243–52. doi:10.1093/fampra/cmq115. PMID 21273283. 
  10. "SEER Stat Fact Sheets: Prostate Cancer". http://seer.cancer.gov/statfacts/html/prost.html. Retrieved 18 June 2014. 
  11. 11,0 et 11,1 (en) World Cancer Report 2014, World Health Organization,‎ 2014, Chapter 1.1 p. (ISBN 9283204298)
  12. Baade PD, Youlden DR, Krnjacki LJ (February 2009). "International epidemiology of prostate cancer: geographical distribution and secular trends". Molecular nutrition & food research 53 (2): 171–84. doi:10.1002/mnfr.200700511. PMID 19101947.